<?xml version='1.0' encoding='utf-8'?>
<document id="11768839"><sentence text="The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel."><entity charOffset="14-25" id="DDI-PubMed.11768839.s1.e0" text="tolterodine" /><entity charOffset="118-135" id="DDI-PubMed.11768839.s1.e1" text="ethinyl estradiol" /><entity charOffset="140-154" id="DDI-PubMed.11768839.s1.e2" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.11768839.s1.e0" e2="DDI-PubMed.11768839.s1.e0" /><pair ddi="false" e1="DDI-PubMed.11768839.s1.e0" e2="DDI-PubMed.11768839.s1.e1" /><pair ddi="false" e1="DDI-PubMed.11768839.s1.e0" e2="DDI-PubMed.11768839.s1.e2" /><pair ddi="false" e1="DDI-PubMed.11768839.s1.e1" e2="DDI-PubMed.11768839.s1.e1" /><pair ddi="false" e1="DDI-PubMed.11768839.s1.e1" e2="DDI-PubMed.11768839.s1.e2" /></sentence><sentence text="Tolterodine is an antimuscarinic agent for the treatment of overactive bladder, a chronic condition that is particularly common in women"><entity charOffset="0-11" id="DDI-PubMed.11768839.s2.e0" text="Tolterodine" /></sentence><sentence text=" Given the prevalence pattern of overactive bladder and the widespread use of oral contraception, circumstances are likely to arise in which physicians may wish to prescribe tolterodine for patients already taking oral contraceptives"><entity charOffset="174-185" id="DDI-PubMed.11768839.s3.e0" text="tolterodine" /></sentence><sentence text=" Based on a search of MEDLINE from 1990 to 2001, there have been no studies of whether concomitant use of these agents entails a risk of drug-drug interaction or conception" /><sentence text="" /><sentence text="This study investigated the effects of tolterodine on the pharmacokinetics and pharmacodynamics of a low-dose combination oral contraceptive (ethinyl estradiol 30 microg/levonorgestrel 150 microg)"><entity charOffset="39-50" id="DDI-PubMed.11768839.s6.e0" text="tolterodine" /><entity charOffset="142-159" id="DDI-PubMed.11768839.s6.e1" text="ethinyl estradiol" /><entity charOffset="170-184" id="DDI-PubMed.11768839.s6.e2" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.11768839.s6.e0" e2="DDI-PubMed.11768839.s6.e0" /><pair ddi="false" e1="DDI-PubMed.11768839.s6.e0" e2="DDI-PubMed.11768839.s6.e1" /><pair ddi="false" e1="DDI-PubMed.11768839.s6.e0" e2="DDI-PubMed.11768839.s6.e2" /><pair ddi="false" e1="DDI-PubMed.11768839.s6.e1" e2="DDI-PubMed.11768839.s6.e1" /><pair ddi="false" e1="DDI-PubMed.11768839.s6.e1" e2="DDI-PubMed.11768839.s6.e2" /></sentence><sentence text="" /><sentence text="This was an open-label, randomized, 2-period crossover study in healthy women" /><sentence text=" Oral contraception was given for 21 days either alone or in combination with oral tolterodine 2 mg BID (on days 1-14) over two 28-day contraceptive cycles"><entity charOffset="83-94" id="DDI-PubMed.11768839.s9.e0" text="tolterodine" /></sentence><sentence text=" Pharmacokinetic assessments were performed on day 14 based on plasma levels of ethinyl estradiol and levonorgestrel up to 24 hours after dosing and serum tolterodine levels at 1 to 3 hours after dosing"><entity charOffset="80-97" id="DDI-PubMed.11768839.s10.e0" text="ethinyl estradiol" /><entity charOffset="102-116" id="DDI-PubMed.11768839.s10.e1" text="levonorgestrel" /><entity charOffset="155-166" id="DDI-PubMed.11768839.s10.e2" text="tolterodine" /><pair ddi="false" e1="DDI-PubMed.11768839.s10.e0" e2="DDI-PubMed.11768839.s10.e0" /><pair ddi="false" e1="DDI-PubMed.11768839.s10.e0" e2="DDI-PubMed.11768839.s10.e1" /><pair ddi="false" e1="DDI-PubMed.11768839.s10.e0" e2="DDI-PubMed.11768839.s10.e2" /><pair ddi="false" e1="DDI-PubMed.11768839.s10.e1" e2="DDI-PubMed.11768839.s10.e1" /><pair ddi="false" e1="DDI-PubMed.11768839.s10.e1" e2="DDI-PubMed.11768839.s10.e2" /></sentence><sentence text=" The potential for pharmacodynamic interaction was assessed in terms of the risk of failure of suppression of ovulation based on serum levels of estradiol and progesterone measured throughout each cycle"><entity charOffset="145-154" id="DDI-PubMed.11768839.s11.e0" text="estradiol" /><entity charOffset="159-171" id="DDI-PubMed.11768839.s11.e1" text="progesterone" /><pair ddi="false" e1="DDI-PubMed.11768839.s11.e0" e2="DDI-PubMed.11768839.s11.e0" /><pair ddi="false" e1="DDI-PubMed.11768839.s11.e0" e2="DDI-PubMed.11768839.s11.e1" /></sentence><sentence text="" /><sentence text="Twenty-four healthy women (age, 23-41 years [mean, 30 years]; height, 155-178 cm [mean, 167 cm]; body weight, 51-75 kg [mean, 64 kg]) participated in the study" /><sentence text=" There was no evidence of a pharmacokinetic interaction between tolterodine and the steroid hormones in the oral contraceptive used, nor did the oral contraceptive show any relevant pharmacokinetic interaction with tolterodine"><entity charOffset="64-75" id="DDI-PubMed.11768839.s14.e0" text="tolterodine" /><entity charOffset="84-91" id="DDI-PubMed.11768839.s14.e1" text="steroid" /><entity charOffset="215-226" id="DDI-PubMed.11768839.s14.e2" text="tolterodine" /><pair ddi="false" e1="DDI-PubMed.11768839.s14.e0" e2="DDI-PubMed.11768839.s14.e0" /><pair ddi="false" e1="DDI-PubMed.11768839.s14.e0" e2="DDI-PubMed.11768839.s14.e1" /><pair ddi="false" e1="DDI-PubMed.11768839.s14.e0" e2="DDI-PubMed.11768839.s14.e2" /><pair ddi="false" e1="DDI-PubMed.11768839.s14.e1" e2="DDI-PubMed.11768839.s14.e1" /><pair ddi="false" e1="DDI-PubMed.11768839.s14.e1" e2="DDI-PubMed.11768839.s14.e2" /></sentence><sentence text=" Serum levels of estradiol and progesterone indicated suppression of ovulation in both treatment periods"><entity charOffset="17-26" id="DDI-PubMed.11768839.s15.e0" text="estradiol" /><entity charOffset="31-43" id="DDI-PubMed.11768839.s15.e1" text="progesterone" /><pair ddi="false" e1="DDI-PubMed.11768839.s15.e0" e2="DDI-PubMed.11768839.s15.e0" /><pair ddi="false" e1="DDI-PubMed.11768839.s15.e0" e2="DDI-PubMed.11768839.s15.e1" /></sentence><sentence text="" /><sentence text="In this selected population" /><sentence text=" coadministration of tolterodine did not affect the contraceptive efficacy of a low-dose combination oral contraceptive containing ethinyl estradiol and levonorgestrel"><entity charOffset="21-32" id="DDI-PubMed.11768839.s18.e0" text="tolterodine" /><entity charOffset="131-148" id="DDI-PubMed.11768839.s18.e1" text="ethinyl estradiol" /><entity charOffset="153-167" id="DDI-PubMed.11768839.s18.e2" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.11768839.s18.e0" e2="DDI-PubMed.11768839.s18.e0" /><pair ddi="false" e1="DDI-PubMed.11768839.s18.e0" e2="DDI-PubMed.11768839.s18.e1" /><pair ddi="false" e1="DDI-PubMed.11768839.s18.e0" e2="DDI-PubMed.11768839.s18.e2" /><pair ddi="false" e1="DDI-PubMed.11768839.s18.e1" e2="DDI-PubMed.11768839.s18.e1" /><pair ddi="false" e1="DDI-PubMed.11768839.s18.e1" e2="DDI-PubMed.11768839.s18.e2" /></sentence><sentence text="" /></document>